Does elevated homocysteine contribute to endothelial dysfunction and cardiovascular risk?

Elevated homocysteine is biologically linked to vascular dysfunction, especially at clearly elevated concentrations (commonly >15 μmol/L), but this does not establish that modest or “above-optimal” values should independently drive preventive treatment in a 52-year-old man.

Vascular and thrombotic effects

• Endothelial dysfunction is well supported. Homocysteine inhibits endothelial DDAH, causing asymmetric dimethylarginine (ADMA) accumulation; ADMA inhibits eNOS and reduces nitric-oxide production. Marked elevations (mean ~35 μmol/L) have been associated with lower flow-mediated dilation (FMD). Across 21 folic-acid trials, FMD generally improved, although folate may have endothelial effects beyond homocysteine lowering.
• Pro-thrombotic signaling is mechanistically credible. Reported effects include increased tissue-factor/thrombin activity, platelet and von Willebrand factor–mediated adhesion, and impaired fibrinolysis with denser, plasmin-resistant fibrin. An early meta-analysis reported an odds ratio of 2.95 for first VTE, but later adjusted studies were inconsistent; B-vitamin lowering did not reduce VTE in trials including HOPE-2 and VITRO.

Oxidative and clinical-risk context

• Oxidative stress is plausible but not proven as a direct human causal effect. In 100 men, the highest homocysteine quintile had 28.2% higher adjusted F₂-isoprostanes than the lowest, yet B-vitamin lowering did not reduce 8-isoprostane in coronary disease.
• Observational cohorts (MESA, NHANES III) found >15 μmol/L predicted cardiovascular events or mortality and modestly improved risk reclassification. However, renal function, nutrition, inflammation, smoking, and other factors may contribute to both homocysteine elevation and risk.

Bottom line

• Homocysteine can contribute to endothelial and pro-thrombotic biology, but lowering it has generally not improved major cardiovascular outcomes. Evidence does not establish preventive actionability for high-normal values or demonstrate that it becomes clinically relevant before vascular-injury markers are abnormal.